BIOTRONIK Receives CE Approval for the World’s First Pacemaker and CRT-P Family Approved for Left Bundle Branch Pacing

The Amvia family enables physiological pacing and workflow optimization to help physicians deliver exceptional patient-centric care with less effort.

 

BIOTRONIK, a leading global medical technology company with 60 years of experience in developing trusted cardiovascular and endovascular solutions, announced today the latest addition to its cardiac rhythm management portfolio. "We are excited to have received CE mark for our newest technology – the world’s first pacemakers and CRT-Ps approved for left bundle branch pacing. Amvia Sky and Amvia Edge represent cutting-edge innovation and incorporate the latest cardiology trends," says Dr. Andreas Hecker, President CRM/EP at BIOTRONIK. In 1963, BIOTRONIK introduced the first German implantable pacemaker and is still driven today by this innovative spirit as it continues to advance the cardiovascular market.

Left bundle branch area pacing (LBBAP) is a relatively new, more physiologic approach in cardiac pacing. Previous studies pointed out that physiologic pacing could maintain or even improve cardiac function and improve long-term clinical outcomes compared to conventional right ventricular pacing.5,6,7 In a recent multi-center study, Prof. Dr. Jan De Pooter, Cardiology and Electrophysiology at the University Hospital Ghent claims that “LBBAP using BIOTRONIK conduction system tools is a safe and reliable treatment option. It is associated with high implant success, low pacing thresholds and high safety profile.”8 The Amvia family now ties in perfectly with these tools.

 
Alongside the broad range of choices for physiologic pacing, the Amvia family also offers new tools that automate and streamline many tasks during implantation, in-office follow-ups and remote monitoring. Furthermore, MRI Guard 24/7, the next-generation MRI access addition, provides an automatic MRI mode switch for easy examinations without pre- and post-scan programming appointments9,10 – for the benefit of both care teams and patients. Prof. Dr. Justin Mariani, Associate Professor, The Alfred Hospital Heart Centre, Melbourne, Australia, is leading the first in-human study of the Amvia system called BIO|CONCEPT Amvia. "The advantages of the Amvia family look very promising. The systems include several physiologic pacing and time-saving functions that will improve clinical workflows and patient care," says Prof. Mariani. Final results of the study are expected later this year.

BIOTRONIK's latest innovative family of pacemaker and CRT-P systems embodies the company's dedication to patient-centric technology for better patient care and workflow simplification to address healthcare provider needs. With 60 years of experience, BIOTRONIK continues its mission to perfectly match technology with the human body in order to deliver better patient outcomes.

 

 

Back